1. Home
  2. MLTX

as 10-07-2025 3:30pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Founded: 2021 Country:
Switzerland
Switzerland
Employees: N/A City: ZUG
Market Cap: 535.3M IPO Year: N/A
Target Price: $37.63 AVG Volume (30 days): 9.7M
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.79 EPS Growth: N/A
52 Week Low/High: $5.95 - $62.75 Next Earning Date: 11-06-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Stock Insider Trading Activity of MoonLake Immunotherapeutics (MLTX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Chen Bihua MLTX Other Sep 30 '25 Sell $6.96 5,827 $40,555.92 1,994,173
Chen Bihua MLTX Other Sep 29 '25 Sell $7.99 6,494,151 $46,827,628.18 1,994,173

Share on Social Networks: